These pharmacokinetic profiles validate the feasibility of repurposing these drugs for H. pylori–associated gastric cancer, as their favorable drug-likeness and bioavailability support their potential to effectively target hub genes like CXCL1, CCL20, and IL12B, which drive inflammation and immune dysregulation. The gene discussed is CXCL1; the disease is gastric cancer.